Vital trace elements (e.g. Zn,Cu) play an essential role in physiological processes, but the disruption of their homeostasis is the cause/consequence of many modern folk diseases (e.g. Alzheimer’s disease). Understanding the transport processes of vital metal ions and their regulation can help not only to develop more effective chelating methods, but also to influence certain processes at the level of transcription. Platinum-containing compounds that have been used to cure cancer since the 1980s are an effective antidote for many cancer types. However, the serious side effects that often accompany their use and the phenomenon of resistance require a deeper understanding of the causes that led to their development and the development of new compounds. Over the last two decades, the anticancer effect of several transient metals (Pt,Ru,Cu) and p-field element (Ga,As) has been described, but their use as medicinal products (except As) is inhibited by a number of factors. Therefore, understanding their mode of action and biotransformation processes is essential for further drug development. Bioaccumulation of toxic metal ions (e.g. Cd,Hg) poses a significant health and environmental risk, simple but selective detection of small amounts in biological and environmental samples is a major problem. The aim of our tender is to explore new opportunities (i) in the development of pharmaceutical candidate metal complexes and complexes, in the exploration and delivery of biospeciation (ii) in the treatment of diseases associated with the disruption of metal ion homoostasis and (iii) in the selective detection of metal ions in biological/environmental samples, by approaching the above three seemingly distinct groups of metal ions/metal compounds. On the one hand, the novelty of the research project is the complex approach to the interaction of drug candidate small molecules with biological systems. Detailed analysis of structural/thermodynamic/kinetic parameters and biological activity helps to understand the mechanism of action, the pharmacokinetic properties, the development of adverse reactions, as well as more effective rational drug development. On the other hand, the innovative solutions to be used (e.g. directed and timed delivery of pharmacocones, remobilisation of metal ions bound in Alzheimer’s plaques, development of multi-regulated artificial nuclease enzymes) could reveal new opportunities for drug-labelled compounds; in the development of metal complexes and complexes. Within the framework of this call, the participants plan to develop an interdisciplinary workshop through the coordinated activities of groups with different knowledge profiles but working in closely related areas in the field of the application. The aim is to identify and strengthen synergies arising from the interdisciplinary nature of work. The two main topics and subthemes of the proposal are: A. development of medicinal compounds containing metal ion 1. Development and testing of metal complexes expected to have anti-cancer effect 2. Development of complex regulation catalytic compounds likely to have therapeutic effects 3. Better delivery of drug-labelled molecules B. Studies on homeostasis of metal ions and its overturning 1. New ways to treat Alzheimer’s disease 2. Metal ion homoostasis transport processes and metal ion detection More detailed extremity of the research directions can be specified below: A. development of medicinal compounds containing metal ion A/1. The development and testing of metal complexes with anti-cancer effect The more general and complex characterisation of pharmacocones, their chemical properties and their interaction with relevant endogenous ligands, transport and cellular proteins, DNA, seems essential for more effective drug development. Revealing the relationship between thermodynamic/kinetic parameters and biological activity that we want to define helps to understand the mechanism of action, the pharmacokinetic properties and the development of adverse reactions, as well as the more effective rationalised drug development. For the analysis of intracellular accumulation and localisation of pharmacokinetics, fluorescent metal compounds are planned to be synthesised (see below). (B/2). We try to reduce side effects and increase selectivity by increasing the effectiveness of the target administration by using different ‘prodrug’ strategies (see below). A/3). Biological effects are planned for both human cancer and normal cell lines. The compounds to be tested include (organic metal) compounds of transition metal ions (e.g. Ru,Pt,Rh) and some (Ga,As) p-field elements. Among the potential ligands, we prioritise molecules with antitumor action (thiosemicarbazones, quinoolinols, compounds of natural origin). A/2 Development of potentially curative catalytic compounds operating on the principle of complex regulation